See Credit Details Below
While the COVID-19 pandemic caused tragedy for millions of families worldwide, it has also spurred concomitant advancements in health care, not the least of which include the first-ever regulatory approvals of therapies based on messenger RNA (mRNA) technology granted to Moderna and BioNTech (in collaboration with Pfizer). At the dawn of this new era in therapeutics, companies operating in this space are eager to develop and commercialize new mRNA-based drugs, but are also faced with the significant challenge of navigating an exceedingly complex IP, competitive, and litigation landscape.
This session will provide registrants with:
- a detailed survey of the current patent and patent litigation landscape for mRNA and lipid nanoparticle delivery technologies [35 minutes]
- in-depth patent data and trends relating to what aspects of mRNA and lipid nanoparticles innovators are seeking protection on (including cutting-edge modifications to the lipids, mRNA payloads, and related novel functions and indications) [10 minutes]
- analytical frameworks for companies that operate in this space to utilize when navigating these complicated issues [15 minutes]
Who Should Attend: In-house counsel, outside attorneys, litigators, IP, health care, and other allied professionals interested in the mRNA and lipid nanoparticle landscape
Program Level: Overview
Advanced Preparation: None
Daniel L. Shores
Rothwell, Figg, Ernst & Manbeck, P.C.